SCHEMBL10013883

SCHEMBL10013883

CC1=CNCCC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10296592 0.92
SCHEMBL27294620 0.90
SCHEMBL257428 0.82
SCHEMBL9911103 0.67
SCHEMBL19006108 0.67
SCHEMBL9910065 0.67
SCHEMBL28840259 0.67
SCHEMBL14530733 0.67
SCHEMBL25735657 0.67
SCHEMBL19353698 0.67

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230046859-A1 Bicyclic Compounds and their Uses NOVARTIS PHARMA AG (CH) 2023-02-16 US disclosed
WO-2022238694-A1 VINYL ISOCYANIDE COMPOUNDS AS ANTIBACTERIAL AGENTS THE UNIVERSITY OF BATH (GB) 2022-11-17 WO disclosed
WO-2018100048-A1 2-PHENYL-2H-PYRAZOLO[3,4-D]PYRIDAZINE DERIVATIVES HAVING ACTIVITY AGAINST PAIN LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2018-06-07 WO disclosed
EP-3170824-A1 6-([1,2,4]TRIAZOLO[4,3-A]PYRIDIN-3-YLMETHYL)-1,6-NAPHTHYRIDIN-5(6H)-ONE DERIVATIVES AS C-MET INHIBITORS Amgen, Inc (US) 2017-05-24 EP disclosed
US-9540370-B2 Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors ABBVIE DEUTSCHLAND GMBH & CO., KG. (DE) 2017-01-10 US disclosed
EP-3093289-A1 [1,2,4]TRIAZOLO[4,3-A]PYRIDINE DERIVATIVES USEFUL AS INHIBITORS OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR Amgen, Inc (US) 2016-11-16 EP disclosed
US-20160297815-A1 7-AZAINDOLE OR 4,7-DIAZAINDOLE DERIVATIVES AS IKK EPSILON AND TBK1 INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME GREEN CROSS CORPORATION (KR) 2016-10-13 US disclosed
EP-2081931-B1 [1,2,4]Triazolo[4,3-a]pyridine derivatives useful as inhibitors of the hepatocyte growth factor receptor AMGEN INC (US) 2016-08-31 EP disclosed
US-20150274724-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE AS GLYCOGEN SYNTHASE KINASE-3 INHIBITORS AbbVie Deutschland GmbH & Co. KG (DE) 2015-10-01 US disclosed
US-9090592-B2 Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors AbbVie Deutschland GmbH & Co. KG (DE) 2015-07-28 US disclosed
US-8481496-B2 Gold (III) complexes with oligopeptides functionalized with sulfur donors and use thereof as antitumor agents UNIVERSITA' DEGLI STUDI DI PADOVA (IT) 2013-07-09 US disclosed
EP-2578583-A1 Fused heterocyclic derivatives and methods of use Amgen Inc. (US) 2013-04-10 EP disclosed
US-20120172376-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE AS GLYCOGEN SYNTHASE KINASE-3 INHIBITORS ABBOTT GMBH & CO. KG (DE) 2012-07-05 US disclosed
US-20120101044-A1 GOLD (III) COMPLEXES WITH OLIGOPEPTIDES FUNCTIONALIZED WITH SULFUR DONORS AND USE THEREOF AS ANTITUMOR AGENTS UNIVERSITA' DEGLI STUDI DI PADOVA 2012-04-26 US disclosed
WO-2010123139-A1 ARYLCARBOXAMIDE DERIVATIVE HAVING SULFAMOYL GROUP 持田製薬株式会社 (JP) 2010-10-28 WO disclosed
WO-2009143477-A1 HETEROCYCLES AS PROTEIN KINASE INHIBITORS AMGEN INC. (US) 2009-11-26 WO disclosed
WO-2009091374-A2 FUSED HETEROCYCLIC DERIVATIVES AND METHODS OF USE AMGEN INC. (US) 2009-07-23 WO disclosed
WO-2009073818-A1 COMPOUNDS AND THERAPEUTIC USE THEREOF MYRIAD GENETICS, INC. (US) 2009-06-11 WO disclosed